补充膳食纤维的肠内营养在危重症患者中的疗效:随机对照试验的系统评价与Meta分析及试验序贯分析
该系统评价与Meta分析纳入20项随机对照试验、共1405例成年危重症患者,比较补充膳食纤维的肠内营养与安慰剂或常规护理。常规Meta分析显示,补充膳食纤维的肠内营养与总体死亡率显著降低相关(RR 0.66,95%CI 0.47–0.92,p=0.01,I²=0%;12项研究),与腹泻发生率显著降低相关(RR 0.70,95%CI 0.51–0.96,p=0.03,I²=51%;11项研究)。但两项结局均被评为具有非常严重的偏倚风险,试验序贯分析提示不能排除1型错误;主要结局未见亚组差异。作者结论为极低确定性证据提示补充膳食纤维的肠内营养具有临床获益,需要大样本高质量多中心随机对照试验来证实任何常规使用的明确推荐。
要点
- 纳入20项RCT、1405例成年危重症患者,比较补充膳食纤维的肠内营养与安慰剂或常规护理。
- 常规Meta分析:补充膳食纤维的肠内营养组总体死亡率降低(RR 0.66,95%CI 0.47–0.92,p=0.01,I²=0%;12项研究)。
- 腹泻发生率降低(RR 0.70,95%CI 0.51–0.96,p=0.03,I²=51%;11项研究)。
- 两项结局均评为非常严重的偏倚风险,试验序贯分析提示不能排除1型错误,证据确定性为极低。
- 主要结局未见亚组差异;作者认为需要大样本高质量多中心RCT来证实任何常规使用的明确推荐。
适用人群与场景
- 成年危重症患者(纳入随机对照试验的研究对象)。
研究设计与关键结果
- 研究类型:随机对照试验的系统评价与Meta分析,并做试验序贯分析;检索MEDLINE、EMBASE、CENTRAL,自建库至2024年1月,2024年6月更新;PROSPERO注册号CRD42023492829。
- 共纳入20项研究、1405例危重症患者;干预为补充膳食纤维的肠内营养,对照为安慰剂或常规护理。
- 主要结局总体死亡率:补充膳食纤维的肠内营养组较对照组降低(RR 0.66,95%CI 0.47–0.92,p=0.01,I²=0%;12项研究)。
- 次要结局腹泻发生率:补充膳食纤维的肠内营养组较对照组降低(RR 0.70,95%CI 0.51–0.96,p=0.03,I²=51%;11项研究)。
- 两项结局均被评为非常严重的偏倚风险,试验序贯分析提示不能排除1型错误。
- 主要结局未见亚组差异。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析(含试验序贯分析)。
- 证据确定性:极低确定性证据。
- 局限:两项结局均评为非常严重的偏倚风险;试验序贯分析提示不能排除1型错误;作者指出需要大样本高质量多中心随机对照试验来证实任何常规使用的明确推荐。
对床旁实践的改变
- 作者结论:极低确定性证据提示补充膳食纤维的肠内营养具有临床获益,但需要大样本高质量多中心随机对照试验来证实任何常规使用的明确推荐。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence on the benefits of fiber-supplemented enteral nutrition (EN) in critically ill patients is inconsistent, and critical care nutrition guidelines lack recommendations based on high-quality evidence. This systematic review and meta-analysis (SRMA) aims to provide a current synthesis of the literature on this topic.
METHODS: For this SRMA of randomized controlled trials (RCT), electronic databases (MEDLINE, EMBASE, CENTRAL) were searched systematically from inception to January 2024 and updated in June 2024. Trials investigating clinical effects of fiber-supplemented EN versus placebo or usual care in adult critically ill patients were selected. Two independent reviewers extracted data and assessed the risk of bias of the included studies. Random-effect meta-analysis and trial sequential analysis (TSA) were conducted. The primary outcome was overall mortality, and one of the secondary outcomes was diarrhea incidence. Subgroup analyses were also performed for both outcomes.
RESULTS: Twenty studies with 1405 critically ill patients were included. In conventional meta-analysis, fiber-supplemented EN was associated with a significant reduction of overall mortality (RR 0.66, 95% CI 0.47, 0.92, p = 0.01, I2 = 0%; 12 studies) and diarrhea incidence (RR 0.70, 95% CI 0.51, 0.96, p = 0.03, I2 = 51%; 11 studies). However, both outcomes were assessed to have very serious risk of bias, and, according to TSA, a type-1 error cannot be ruled out. No subgroup differences were found for the primary outcome.
CONCLUSION: Very low-certainty evidence suggests that fiber-supplemented EN has clinical benefits. High-quality multicenter RCTs with large sample sizes are needed to substantiate any firm recommendation for its routine use in this group of patients. PROSPERO registration number: CRD42023492829.
参考来源
- Koch JL, Lew CCH, Kork F, et al. The efficacy of fiber-supplemented enteral nutrition in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Crit Care. 2024. PMID: 39511681. doi:10.1186/s13054-024-05128-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。